Conference
A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC
Abstract
BACKGROUND: Vascular endothelial growth factor (VEGF) and c-kit are highly expressed in adenoid cystic carcinoma (ACC) and associated with biologic aggressiveness. This study aimed to assess the antitumor activity of sunitinib, a multi-targeted inhibitor of vascular endothelial growth factor receptor, c-kit, platelet-derived growth factor receptor, ret proto-oncogene (RET) and FMS-like tyrosine kinase 3 (FLT3), in ACC of the salivary gland.
Authors
Chau NG; Hotte SJ; Chen EX; Chin SF; Turner S; Wang L; Siu LL
Volume
23
Pagination
pp. 1562-1570
Publisher
Elsevier
Publication Date
June 2012
DOI
10.1093/annonc/mdr522
Conference proceedings
Annals of Oncology
Issue
6
ISSN
0923-7534